European Companies Search Engine

EU funding (€3,345,728): European doctoral network for proofreading the proteome Hor 9 Jul 2026 EU Research and Innovation programme "Horizon"

Overview

Text

European doctoral network for proofreading the proteome

Targeted Protein Degradation (TPD), an innovative strategy to redirect the cellular degradation machinery towards the elimination of disease-relevant proteins, has attracted enormous attention from researchers, industry and clinicians. TPD is based on the capacity of a small molecule, the degrader, to re-route the ubiquitination machinery towards a selected protein of interest to trigger its ubiquitination and degradation by the Ubiquitin Proteasomal System, via its interaction with specific E3 ubiquitin ligases. ProofReading will bring together a diverse community, assembling the necessary multidisciplinary expertise to develop novel TPD approaches applicable to various cellular and disease contexts, facilitating the generation of degraders. ProofReading will establish an interdisciplinary, intersectoral and international research programme to drive the development of tools, degraders and innovative strategies aimed at eliminating targets involved in cancer, infection, inflammation and rare diseases. The network comprises 10 universities, 4 research centres and 8 innovative companies, which will provide state-of-the-art training for the recruited Doctoral Candidates (DCs). This is the only doctoral network related to proteome proofreading by using TPD that combines the knowledge in all disciplines, ranging from life to physical sciences, required to develop a degrader. Interdisciplinary and intersectoral secondments will expose the DCs to different working environments. We will organize 5 hands-on research workshops on central methodological and technical aspects of TPD and 7 courses on transferable skills, of primary importance for increasing the employability of the DCs. We will also address the important issue of mental health and well-being in science. ProofReading will train 11 researchers with specific knowledge in the cutting-edge technology of TPD, which will contribute to the generation of future drugs to treat diseases.


Funded Companies:

Company name Funding amount
Atlas Molecular Pharma SL ?
Asociacion Centro de Investigacion CRL en Biociencias Cic Biogune €564,376
Astrazeneca UK Ltd. €348,738
Bruker Daltonics GmbH & Co. KG €290,272
Centre National de la Recherche Scientifique CNRS €314,669
Ecole Polytechnique Federale DE Lausanne €380,642
Forschungsinstitut FUR Molekulare Pathologie GmbH €302,543
Johann Wolfgang Goethe-Universitaet Frankfurt AM Main €290,272
Philipps Universitaet Marburg €290,272
Universita Degli Studi Di Milano €281,755
Universitat de Barcelona €282,188

Source: https://cordis.europa.eu/project/id/101311289

The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Atlas Molecular Pharma SL, Derio, Spain.